The Efficacy and Safety of Ezetimibe for Treatment of Dyslipidemia After Heart Transplantation
Authors:
- M.G. Crespo-LeiroMCM.G. Crespo-Leiro
- M.J. PaniaguaMPM.J. Paniagua
- R. MarzoaRMR. Marzoa
- Z. GrilleZGZ. Grille
- C. NayaCNC. Naya
- X. FloresXFX. Flores
- J.A. RodriguezJRJ.A. Rodriguez
- V. MosqueraVMV. Mosquera
- R. FrancoRFR. Franco
- A. Castro-BeirasACA. Castro-Beiras
- 1 November 2008
- journal article
- Published by Elsevier in Transplantation Proceedings
- Vol. 40 (9) , 3060-3062
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Ezetimibe Reduces Low-Density Lipoprotein Cholesterol (LDL-C) in Renal Transplant Patients Resistant to HMG-CoA Reductase InhibitorsAmerican Journal of Therapeutics, 2007
- Ezetimibe treatment in hypercholesterolaemic kidney transplant patients is safe and effective and reduces the decline of renal allograft function: a pilot studyNephrology Dialysis Transplantation, 2007
- Treatment of Hypercholesterolemia With Ezetimibe in Cardiac Transplant RecipientsThe Journal of Heart and Lung Transplantation, 2007
- Ezetimibe in Renal Transplant Patients with Hyperlipidemia Resistant to HMG-CoA Reductase InhibitorsTransplantation, 2006
- A Retrospective Analysis of Ezetimibe Treatment in Renal Transplant RecipientsAmerican Journal of Transplantation, 2006
- Safety of Statins When Response is Carefully Monitored: A Study of 336 Heart RecipientsTransplantation Proceedings, 2005
- Drug Therapy in the Heart Transplant RecipientCirculation, 2005
- Drug Therapy in the Heart Transplant RecipientCirculation, 2005
- Simvastatin Reduces Graft Vessel Disease and Mortality After Heart TransplantationCirculation, 1997
- Effect of Pravastatin on Outcomes after Cardiac TransplantationNew England Journal of Medicine, 1995